- Provide guidance on Atom Bioworks' strategic aims.- As corresponding author, oversee completion of a publication detailing Atom Bioworks' recent therapeutic successes in the use of proprietary nucleic acid scaffolds against Acute Myeloid Leukemia (AML) in vitro and in vivo.

- Led the R&D team to FDA pre-EUA for the application of Nucleic acid scaffold (Nas) technology in a SARS-CoV-2 lateral flow assay.- Designed and executed a Nas development program that resulted in the patent conversion of "Multispecific Polynucleotide Nanostructures for Cancer Detection and Therapy":1) Nas scaffolds enhance aptamer affinity (avidity) to binding strengths similar - and sometimes better - than antibodies.2) The selection of proprietary aptamers against acute myeloid leukemia (AML), and proved the specific cell killing of these aptamers. 3) Demonstrated that these aptamers on Nas scaffolds enhance leukemia cell sensitivity to daunorubicin, both via MTT cell killing assays and flow cytometry IC50 assays.4) Programming of ligand patterns and densities on Nas scaffolds enabled selective killing of AML cells based on targeted cell surface expression profiles.

Developing, reducing to practice, and commercializing Nucleic acid scaffold (Nas) platform technology as diagnostics and theranostics with the mission of detecting and destroying viruses and cancer cells.

Dencoda, LLC is reducing to practice kinase identification and drugging technologies via the usage of synthetic substrates for application to clinical diagnostics.

- Directly managed $1.5 million in client accounts. - Subject matter expert (SME)/Franchise leader in the following markets: - Hemophilia (A, B, and bypass agents) - Anticoagulants and anticoagulant reversal - Alpha-1 antitrypsin deficiency - Albumin

• Co-investigator; "Young Innovators Program" Student Science Enrichment Program (SSEP) Burroughs Wellcome Fund. Grant awarded 8/31/2017 and provides funding of $180,000 for 3 years. • Reviewer; International Journal of STEM Education.• PI, NC TraCS # 2KR1091802, “In vitro selection of non-binding ssDNA oligos with high serum nuclease resistance”

As the first Institute Fellow at the Eshelman Institute for Innovation, I:• Managed a $70,000 budget for the 2017 year of the Young Innovators Program.• Pioneered the EII Institute Fellowship.• Served as a member of the EII Founding and Administrative Teams.• Served as primary proposal reviewer for 56 EII proposals across three funding rounds.• Served as a voting member of the funding panel for the April and November 2016 student and postdoc funding rounds.• Founded and directed the EII Young Innovators Program (YIP) for highschool students (http://unceii.org/programs/young-innovators-program/) o Managed a team composed of 1 senior faculty and 7 PharmD Candidates. o Executed the YIP 2016 Pilot Program: 17 interns from 9 area high schools. o Negotiated 10 new partnerships between the YIP and industrial, academic, secondary school, and government entities. o Received $7500 in corporate donations. o Grant proposal to the Burroughs Wellcome Fund Student Science Enrichment Program received Finalist status. o Grant proposal to the NSF ITEST (potential award of $1.2 million) received Competitive status.• Led the development of a predictive model for early-stage healthcarestartup success to guide future EII spinout investment decisions.• Led an early-stage startup venture, PharmaQuant, aimed at developing a rapid antibiotic serum level test kit for the critically ill.

• Designed and implemented an aptamer research program to counter FVIII biosimilar immunogenicity.• Developed a panel of DNA aptamers specific for Bacillus anthracis Protective Antigen (PA) to detect subtle conformational changes induced by a variety of mutations.• Trained two high school students as a Howard Hughes Medical Institute (HHMI) Student-Teacher Initiative Program (STIP) Mentor.

• Developed antibody-mimetic Synthetides® for targeted therapeutics and environmental diagnostics.

I executed a research project aimed at the identification of bacterial species present in bioreactors for the enhanced biological removal of phosphate (EBPR). This involved pioneering a HPLC approach to bacterial species identification based upon heavy isotopes of carbon (C-13) and nitrogen (N-15).

I investigated cell surface opacity protein (OPA) variability in Neisseria gonorrhoeae, which is used by this pathogen to evade immunological surveillance.

I investigated the effect that perturbations of cerebroside levels had on neuronal myelination and associated transcription levels of target genes in murine models.